Comparison of two dosages of rabbit antithymocyte globulin (r-ATG) in treating children with severe aplastic anemia.
Comparison of two dosages of rabbit antithymocyte globulin (r-ATG) in treating children with severe aplastic anemia.
复制标题
DOI：
10.1691/ph.2018.7353
复制
发表时间：
2018-05
期刊：
影响因子：
--
通讯作者：
Shaofen Lin;Su Liu;H. Xue;Junbin Huang;Jian Wang;Qihui Chen;Bihong Zhang;Chun Chen
中科院分区：
文献类型：
--
作者：
Shaofen Lin;Su Liu;H. Xue;Junbin Huang;Jian Wang;Qihui Chen;Bihong Zhang;Chun Chen
本研究比较了两种不同剂量兔抗胸腺细胞球蛋白（r-ATG）联合环孢素（CsA）治疗儿童严重再生性贫血（SAA）的疗效和安全性。回顾性分析2005年1月至2017年1月中山大学中山纪念医院122例SAA患儿行r-ATG/CsA的临床资料。55例r-ATG剂量为2.5mg/(kg·d，组1)，67例r-ATG剂量为3.5 mg/(kg·d，组2)，连续给药5 d。治疗后第3、6个月，组2有效率高于组1 （45.5% vs 26.4%， P=0.032; 54.5% vs 35.8%， P=0.042）。治疗后第9、12个月，两组有效率相近（71.2% vs 54.9%， P=0.077; 75.9% vs 68.6%， P=0.399）。两组血清疾病发生率（74.5% vs 79.1%， P=0.551）、短期感染率（76.4% vs 62.7%， P=0.105）、早期死亡率（3.6% vs 1.5%， P=0.447）、3年总生存率（89.5% vs 90.1%， P=0.932）差异均无统计学意义。r-ATG/CSA治疗SAA安全有效。两种r-ATG剂量的最终疗效和安全性相同。但本研究随访时间较短，需进一步随访组间远期并发症及生存率的比较。
In this study, efficacy and safety of two different dosages of rabbit antithymocyte globulin (r-ATG) combined with cyclosporine (CsA) in treating children with severe aplastic anemia (SAA) were compared. The clinical data of 122 SAA children treated by r-ATG/CsA between Jan 2005 and Jan 2017 at Sun Yat-sen Memorial Hospital of Sun Yat-sen University were retrospectively analyzed. The r-ATG dose of 55 cases was 2.5mg/(kg·d, group 1), and in the other 67 cases it was 3.5 mg/(kg·d, group 2). r-ATG was continuously administered for 5 days. In the 3rd and 6th month after treatment, the efficacy rate of group 2 was higher than that of group 1 (45.5% vs 26.4%, P=0.032; 54.5% vs 35.8%, P=0.042). In the 9th and 12th month after treatment, the efficacy rates of both groups were similar (71.2% vs 54.9%, P=0.077; 75.9% vs 68.6%, P=0.399). The incidence rates of serum diseases (74.5% vs 79.1%, P=0.551), short-term infection rates (76.4% vs 62.7%, P=0.105), early mortality (3.6% vs 1.5%, P=0.447), and 3-year overall survival rates (89.5% vs 90.1%, P=0.932) of both groups showed no significant differences. The r-ATG/CSA therapy was safe and effective towards SAA. The final efficacies and safety of the two r-ATG dosages were equal. However, the follow-up period in this study was relatively short, so the intergroup comparison of the long-term complications and survival rates needed to be further followed up.